In a recent feature from Clinical Insider, Novotech announced a strategic partnership with Kyungpook National University Hospital (KNUH), expanding its clinical trial footprint across South Korea.
Key takeaways:
Integrated Early and Late-Phase Trial Execution
Under the new agreement, Novotech will conduct early-phase studies at KNUH’s newly launched Advanced Clinical Trials Center, while late-phase trials will be managed across KNUH’s broader network. The partnership is supported by site management organization Acrostar.
Accelerated Study Start-Up and Enrollment
The collaboration is structured to enhance feasibility, enrollment, and regulatory compliance, with mutual commitments to reduce site contract timelines, ensure trial readiness, and meet enrollment targets.
Alignment with Korea’s Advanced Regenerative Bio Act
This expansion follows Korea’s 2024 amendments to the Advanced Regenerative Bio Act, which broaden access to advanced therapies, including CGTs. Novotech sees these changes as pivotal in positioning Korea as a preferred destination for innovative trials.
Continued Growth in APAC Trial Network
The KNUH deal builds on recent partnerships with Seoul National University Hospital, Ulsan University Hospital, and Wonju Severance Christian Hospital, reinforcing Novotech’s role as a key clinical development partner in the region.
Yooni Kim, Managing Director for APAC at Novotech, stated: “This collaboration enhances our ability to deliver high-quality clinical trials and ensures faster access to transformative therapies for patients.” As the region accelerates biotech innovation, Novotech remains a trusted CRO partner for sponsors navigating complex trials across Asia Pacific and globally.